Decreased Serum Tryptophan and Severe Ulcerative Damage of Colon Mucosa Identify Inflammatory Bowel Disease Patients With High Risk of Cytomegalovirus Colitis
Authors:
- Sophia RüsingSRSophia Rüsing
- Lina WelzLWLina Welz
- Constanze PfitzerCPConstanze Pfitzer
- Danielle Monica HarrisDHDanielle Monica Harris
- Christoph RöckenCRChristoph Röcken
- Philip RosenstielPRPhilip Rosenstiel
- Susanna NikolausSNSusanna Nikolaus
- Florian TranFTFlorian Tran
- Stefan SchreiberSSStefan Schreiber
- Konrad AdenKAKonrad Aden
- Laura Katharina SieversLSLaura Katharina Sievers
Open Access
- 27 June 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 15 (8) , e00731
Abstract
INTRODUCTION: Patients with inflammatory bowel disease (IBD) are predisposed to the reactivation of viral infections such as cytomegalovirus (CMV). Clinical discrimination of disease flares and colonic CMV reactivation is difficult in patients with established diagnosis of IBD, and there are no reliable noninvasive diagnostic tools yet. Furthermore, the influence of novel therapeutics including biologicals and Janus kinase inhibitors on the risk of CMV colitis is unclear. The goal of this study was to identify risk factors and clinical determinants of CMV colitis that could serve as minimally invasive markers both for active CMV colitis and relapse. METHODS: To this end, a retrospective analysis of 376 patients with suspected or confirmed CMV colitis 2016–2023 was performed. RESULTS: Previous administration of systemic steroids increased the odds of CMV colitis to OR 4.6. Biologicals did not change the incidence of CMV colitis but decreased the OR of a relapse to 0.13. Clinical parameters such as severely bloody diarrhea, intense microscopic ulcerative damage, and decreased serum tryptophan correlated with detection of CMV. Importantly, persistent decrease of tryptophan was observed in patients with CMV relapse. Furthermore, tryptophan degradation through the kynurenine pathway was increased in CMV-positive patients. DISCUSSION: Taken together, we identify decreased serum tryptophan as a novel potential minimally invasive marker to aid identification of IBD patients with active CMV colitis and at high risk for relapse.Keywords
Funding Information
- DFG Cluster of Excellence 1261 “Precision medicine in chronic inflammation†(1261)
- e:Med Juniorverbund “Try-IBD†(01ZX1915A)
- e:Med Network GUIDE-IBD (031 L0188A)
- DFG (RU5042)
This publication has 14 references indexed in Scilit:
- Association between metabolites in tryptophan-kynurenine pathway and inflammatory bowel disease: a two-sample Mendelian randomizationScientific Reports, 2024
- Postbiotics: An alternative and innovative intervention for the therapy of inflammatory bowel diseaseMicrobiological Research, 2023
- Targeting Aryl Hydrocarbon Receptor Signaling Enhances Type I Interferon-Independent Resistance to Herpes Simplex VirusMicrobiology Spectrum, 2021
- ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel DiseaseJournal of Crohn's and Colitis, 2021
- Gut Microbiota Regulation of Tryptophan Metabolism in Health and DiseaseCell Host & Microbe, 2018
- Increased Tryptophan Metabolism Is Associated With Activity of Inflammatory Bowel DiseasesGastroenterology, 2017
- Comparison of the Effect of Standard and Novel Immunosuppressive Drugs on CMV-Specific T-Cell Cytokine ProfilingTransplantation, 2013
- Strong association of phenylalanine and tryptophan metabolites with activated cytomegalovirus infection in kidney transplant recipientsHuman Immunology, 2012
- Proinflammatory Cytokines in the Pathogenesis of Inflammatory Bowel DiseasesGastroenterology, 2011
- Inhibition of T Cell Proliferation by Macrophage Tryptophan CatabolismJournal of Experimental Medicine, 1999